ArticleJTCVS open2026
Predicting acute kidney injury in adults after cardiac surgery with a novel clinical metric: The cardiac diuretic-responsiveness index.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Objective: Cardiac surgery-associated acute kidney injury (CSA-AKI) is a common complication after surgery, yet few risk models are used in practice. We evaluated whether a cardiac diuretic responsiveness index (CDRI) can accurately predict CSA-AKI. Methods: Time-series hemodynamic, intake/output volumes, medication, and laboratory data were extracted from electronic health records for 2016 patients who underwent cardiac surgery (2017-2022) and linked to the institutional Society of Thoracic Surgeons Baylor St Luke's Medical Center database. Patients with serum creatinine >4 mg/dL, dialysis before surgery, or those without diuretics administered were excluded. CDRI was defined as urine output in the first hour after initial diuretic administration adjusted for patient weight and diuretic dose (cc/kg/hr/mg furosemide). CSA-AKI was defined by Kidney Disease Improving Global Outcomes creatinine criteria. Segmental regression identified the optimal CDRI threshold. Results: Median time to first dose was 26.4 hours. CSA-AKI occurred in 16.2% (n = 326) of patients who were primarily stage 1 (82.8%, n = 270). Patients who developed CSA-AKI had significantly lower CDRI values (0.0611 vs 0.111 cc/kg/hr/mg furosemide; Conclusions: CDRI outperforms oliguria in predicting CSA-AKI, enabling real-time stratification, and may inform timely intervention to prevent AKI progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.